These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 9756784

  • 1. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
    Mullen AB, Baillie AJ, Carter KC.
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2722-5. PubMed ID: 9756784
    [Abstract] [Full Text] [Related]

  • 2. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.
    Carter KC, Baillie AJ, Mullen AB.
    Clin Diagn Lab Immunol; 1999 Jan; 6(1):61-5. PubMed ID: 9874665
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.
    Mullen AB, Carter KC, Baillie AJ.
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2089-92. PubMed ID: 9333030
    [Abstract] [Full Text] [Related]

  • 4. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
    Banduwardene R, Mullen AB, Carter KC.
    Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
    [Abstract] [Full Text] [Related]

  • 5. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC, Mullen AB, Sundar S, Kenney RT.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.
    Nieto J, Alvar J, Mullen AB, Carter KC, Rodríguez C, San Andrés MI, San Andrés MD, Baillie AJ, González F.
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2781-7. PubMed ID: 12936974
    [Abstract] [Full Text] [Related]

  • 7. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
    Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB.
    Antimicrob Agents Chemother; 2003 May; 47(5):1529-35. PubMed ID: 12709318
    [Abstract] [Full Text] [Related]

  • 8. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
    Yardley V, Croft SL.
    Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
    [Abstract] [Full Text] [Related]

  • 9. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.
    Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E.
    J Am Acad Dermatol; 2007 Apr; 56(4):612-6. PubMed ID: 17276541
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TP, Musa B, Ali MH, Elamin MY, Kirigi G, Juma R, Kip AE, Schoone GJ, Hailu A, Olobo J, Ellis S, Kimutai R, Wells S, Khalil EA, Strub Wourgaft N, Alves F, Musa A.
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [Abstract] [Full Text] [Related]

  • 11. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
    Gangneux JP, Sulahian A, Garin YJ, Derouin F.
    Trans R Soc Trop Med Hyg; 1996 Sep; 90(5):574-7. PubMed ID: 8944278
    [Abstract] [Full Text] [Related]

  • 12. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA, Moreno J, Nieto J, Carter KC, Mullen AB, Ambros L, Rodríguez C, San Andrés MI, González F.
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM.
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [Abstract] [Full Text] [Related]

  • 14. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F.
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [Abstract] [Full Text] [Related]

  • 15. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate.
    Williams DM, Carter KC, Baillie AJ.
    J Drug Target; 1995 May; 3(1):1-7. PubMed ID: 7655816
    [Abstract] [Full Text] [Related]

  • 16. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.
    Roychoudhury J, Sinha R, Ali N.
    PLoS One; 2011 Mar 10; 6(3):e17376. PubMed ID: 21423750
    [Abstract] [Full Text] [Related]

  • 17. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P, Retornaz K, Horelt A, Garnier JM.
    Fundam Clin Pharmacol; 2003 Apr 10; 17(2):183-8. PubMed ID: 12667228
    [Abstract] [Full Text] [Related]

  • 18. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice.
    Carter KC, Dolan TF, Alexander J, Baillie AJ, McColgan C.
    J Pharm Pharmacol; 1989 Feb 10; 41(2):87-91. PubMed ID: 2568434
    [Abstract] [Full Text] [Related]

  • 19. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.
    Clin Infect Dis; 2011 Dec 10; 53(12):e152-8. PubMed ID: 22016502
    [Abstract] [Full Text] [Related]

  • 20. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
    Sinha R, Roychoudhury J, Palit P, Ali N.
    Antimicrob Agents Chemother; 2015 Jan 10; 59(1):344-55. PubMed ID: 25367907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.